Trial Information

A Randomized, Controlled Trial of Target Therapy Plus Chemotherapy in Patients Undergoing Liver Resection for Colorectal Liver Metastases

In patients with colorectal cancer (CRC), the liver is the most common site of hematogenous
metastases. Approximately half of patients develop hepatic metastases during the course of
the disease, and hepatic metastases are responsible for death in at least two thirds of CRC
patients.

Over the past decade, due to the introduction of irinotecan-based or oxaliplatin-based
combination chemotherapy, the median survival among patients with colorectal liver
metastases (CLM) has increased from 6 ~8 months to more than 20 months5.In recent years,
target therapy has rapidly gained attention for the treatment of CLM and is under active
investigation.

Although numerous publications have reported the efficacy of target therapy in combination
treatment for CLM patients, most of these studies focused solely on those patients without
undergoing resection of liver metastases. In contrast, little work has concentrated on
exploring the effection of target therapy for CLM patients undergoing Synchronic
Hepatectomy.